US Earnings Financial Results SEC Filings — May 06, 2026

06-05-2026

PARKE BANCORP, INC. reported robust Q1 2026 financial results with net income of $11,844 thousand (up 52% YoY from $7,778 thousand), driven by net interest income growth of 33% to $22,132 thousand and a reduced provision for credit losses to $202 thousand from $590 thousand. However, total assets contracted 2% QoQ to $2,212,935 thousand, reflecting a 29% decline in cash and cash equivalents to $110,874 thousand and a 3% drop in total deposits to $1,698,744 thousand, while noninterest-bearing deposits fell 16% QoQ. Shareholders' equity increased 3% QoQ to $335,563 thousand supported by earnings retention despite common stock dividends of $2,119 thousand.

• ·Basic EPS $1.01 vs $0.66 YoY; Diluted EPS $0.99 vs $0.65 YoY
• ·Common stock dividend $0.18 per share ($2,119 thousand total); Preferred dividend $15.00 per share ($5 thousand total)
• ·Gross loans increased 0.4% QoQ to $2,043,296 thousand
• ·Non-interest expense increased 10% YoY to $7,214 thousand, with compensation up 13% to $3,704 thousand
• ·Cash flow from operating activities $13,019 thousand vs $6,999 thousand YoY
• ·Net cash used in financing activities $50,799 thousand, driven by deposit outflows

06-05-2026

Polomar Health Services reported revenue of $648,231 for the year ended December 31, 2025, a 1002% YoY increase from $58,824, with gross profit rising to $460,099 from $30,903. However, operating expenses surged to $11,010,363 (primarily G&A at $10,943,795), resulting in a net loss of $(10,701,105) versus $(1,341,333) prior year, while total assets fell to $390,043 from $9,951,773 due to intellectual property amortization, turning stockholders' equity into a $(1,222,329) deficit. Additionally, partner ForHumanity suspended VigorAir sales and signaled intent to terminate the exclusivity agreement amid manufacturing and trial delays.

• ·ForHumanity Agreement: initial 42-month term, exclusivity through June 30, 2026, terminable if average monthly sales < $100,000 for Jan-Jul 2026; forbearance granted on $200,000 payment due Jan 9, 2026.
• ·Preliminary clinical trial results received Feb 12, 2026; complete results Feb 28, 2026.
• ·ForHumanity intent to terminate agreement announced Apr 23, 2026.
• ·Related party promissory notes: $897,660 as of Dec 31, 2025 (down from $1,138,570).
• ·Net loss per share: $(0.39) basic and diluted for 2025 vs $(0.05) for 2024.
• ·Company has not established material recurring revenues; subject to significant related party short-term debt.

06-05-2026

For Q1 2026, MannKind Corp reported total revenues of $90,171 thousand, up 15% YoY from $78,354 thousand, driven by strong growth in commercial product sales (+79% to $33,907 thousand) and royalties (+9% to $32,749 thousand); however, collaborations and services declined 20% to $23,515 thousand, while total expenses surged 64% to $91,838 thousand due to sharp increases in SG&A (+116%) and R&D (+56%), resulting in an operating loss of $1,667 thousand and net loss of $16,619 thousand versus net income of $13,158 thousand in Q1 2025. Cash and equivalents fell to $52,834 thousand from $74,882 thousand at year-end 2025 amid principal repayments on notes. Total assets decreased to $744,403 thousand from $792,182 thousand.

• ·Operating cash flow used $5,365 thousand in Q1 2026 vs $6,377 thousand in Q1 2025.
• ·Net cash used in financing activities $35,406 thousand in Q1 2026 primarily due to $35,502 thousand principal payments on senior convertible notes.
• ·Inventory increased to $49,166 thousand as of March 31, 2026 from $35,313 thousand at December 31, 2025.
• ·Term loan balance $318,722 thousand as of March 31, 2026.
• ·Stockholders' deficit widened to $59,195 thousand from $51,022 thousand at December 31, 2025.

06-05-2026

LTC Properties reported Q1 2026 total revenues of $95,411 up 95% YoY from $49,031, driven by new resident fees and services of $49,585 and higher interest income from financing receivables (+18%) and mortgage loans (+11%). However, rental income declined 16% YoY to $26,339 due to lower contractual and variable rents, while expenses increased 131% to $70,630 including new seniors housing operating expenses of $36,889 and higher interest expense (+36%). Net income available to common stockholders rose 14% to $23,437 with EPS of $0.48 (up 7% YoY), but dividends per share remained flat at $0.57.

• ·Revolving line of credit balance increased to $282,963 at March 31, 2026 from $252,863 at December 31, 2025.
• ·Non-controlling interests decreased to $73,075 at March 31, 2026 from $87,400 at December 31, 2025.
• ·Subsequent to quarter-end: Acquired 61-unit Illinois SHOP community for $9,205 and entered management agreement with new operator; terminated triple-net master lease and converted two communities (159 units, gross book value $32,361) in Georgia and South Carolina to SHOP with new operator.
• ·Investment in real estate properties during Q1: $108,153.

06-05-2026

Advantage Solutions Inc. reported Q1 2026 revenues of $869,601 thousand, up 5.8% YoY from $821,792 thousand, with strong growth in Experiential Services (+22.9%) and modest gains in Retailer Services (+4.3%), but Branded Services revenues declined 11.3% YoY amid sharp drops in branded merchandising (-26.7%) and omni-commerce marketing services (-31.1%). Operating income improved to $4,162 thousand profit from a $14,621 thousand loss, and cash from operations turned positive at $23,728 thousand versus a $39,627 thousand outflow; however, net loss widened to $71,831 thousand from $56,130 thousand due to higher interest, other expenses, and income taxes. Total cash and equivalents fell to $143,870 thousand QoQ from $240,850 thousand, while long-term debt decreased to $1,520,790 thousand from $1,660,611 thousand.

• ·Investments in unconsolidated affiliates decreased to $205,336 thousand from $234,138 thousand QoQ.
• ·Other intangible assets, net declined to $951,593 thousand from $993,927 thousand QoQ.
• ·Proceeds from divestitures of $40,919 thousand in investing activities.
• ·Principal payments on long-term debt of $131,319 thousand in financing activities.

06-05-2026

HNI Corporation reported net sales of $1,347.5 million for the quarter ended April 4, 2026, more than doubling YoY from $599.8 million, driven by apparent acquisition impacts including inventory step-up. However, the company swung to an operating loss of $36.4 million from a $24.4 million profit, due to elevated selling and administrative expenses ($514.8 million vs $207.6 million), restructuring charges ($18.0 million vs $6.4 million), and acquisition costs ($3.5 million), resulting in a net loss of $38.8 million (EPS -$0.55) versus net income of $13.9 million (EPS $0.29). Operating cash flow deteriorated sharply to -$171.8 million from $12.6 million amid significant working capital changes.

• ·Restructuring and impairment charges increased to $18.0M from $6.4M YoY.
• ·Acquisition costs of $3.5M recorded in Q1 2026.
• ·Inventory step-up non-cash charge of $31.3M in operating cash flow.
• ·Investment in unconsolidated affiliates: $45.7M purchases offset by $8.0M proceeds.
• ·Total assets decreased to $4,772.6M from $4,885.0M QoQ.
• ·Long-term debt increased to $1,426.8M from $1,276.9M QoQ.
• ·Cash dividends paid: $24.7M ($0.34 per share) in Q1 2026 vs $15.5M ($0.33 per share) in Q1 2025.

06-05-2026

For Q1 2026, Owens Corning reported net sales of $2,265 million, down 10% YoY from $2,530 million, with gross margin declining sharply 30% to $510 million from $725 million, resulting in operating income of $120 million versus $407 million. While the net loss from discontinued operations improved to $(143) million from $(348) million, overall net loss widened slightly to $(104) million from $(93) million, and diluted EPS deteriorated to $(1.29) from $(1.08). Cash used in operating activities increased to $(154) million from $(49) million.

• ·Short-term debt increased to $383M from $50M QoQ.
• ·Total equity declined to $3,683M from $3,893M QoQ.
• ·Property, plant and equipment net at $4,121M as of March 31, 2026.

06-05-2026

Myriad Genetics reported Q1 2026 revenue of $200.4M, up 2.3% YoY from $195.9M, driven by strong growth in Mental Health (+23.5%) and Cancer Care Continuum (+4.0%), though offset by a 15.0% decline in Prenatal Health. Gross profit rose 2.6% to $137.6M, but operating expenses increased 3.1% to $168.3M including $5.4M in impairment charges, resulting in a wider operating loss of $30.7M (vs $29.0M) and net loss of $34.1M (vs $0.1M). Cash and equivalents decreased to $124.4M from $149.6M at year-end, with stockholders' equity falling to $337.4M.

• ·Net cash used in operating activities improved slightly to $15.7M from $16.3M YoY.
• ·Total assets decreased to $673.7M from $706.6M at December 31, 2025.
• ·Long-term debt stable at $120.3M.
• ·Stock-based compensation expense $6.5M in Q1 2026 vs $9.5M in Q1 2025.

06-05-2026

BeOne Medicines Ltd. reported strong Q1 2026 results with net income surging to $227,357 from $1,270 in Q1 2025, comprehensive income of $252,059 (up from $7,937), and other revenue increasing to $26,109 (from $8,749), driven by Amgen royalty ($18,297) and Novartis broad markets ($5,263). Cash from operating activities rose sharply to $201,336 from $44,082, supporting cash and equivalents of $4,791,676 (up from $4,547,530 at Dec 31, 2025). However, R&D expenses climbed to $29,403 from $20,707 YoY, short-term debt increased to $116,140, and accumulated deficit remained high at $8,092,546.

• ·Amgen royalty revenue: $18,297 (Q1 2026) vs $5,519 (Q1 2025)
• ·Novartis broad markets revenue: $5,263 (Q1 2026) vs $3,522 (Q1 2025)
• ·Net cash used in investing activities: $45,510 (Q1 2026) vs $121,941 (Q1 2025)
• ·Remaining portion of development funding cap: $72,346 as of Mar 31, 2026
• ·Share-based compensation expense: $123,355 (Q1 2026) vs $95,478 (Q1 2025)

06-05-2026

VITASPRING BIOMEDICAL CO. LTD. reported zero revenues for both the three months ended October 31, 2024 and 2023, and for the nine months ended October 31, 2024 versus 2023, with net losses improving to $196,292 (from $234,980) and $631,785 (from $893,164) respectively due to lower SG&A expenses. However, total assets declined sharply 57.5% to $58,382 from $137,342 as of January 31, 2024, driven by reductions in long-term assets, while liabilities rose 12.7% to $3,930,445, widening the stockholders' deficit to $3,872,063. Cash increased modestly to $2,062 from $13, supported by reduced operating cash burn of $12,885 versus $32,297 for the nine months.

• ·Equipment and vehicle, net declined to $16,595 from $24,063 as of January 31, 2024.
• ·Accounts payable - related party steady at $2,411,000.
• ·Stock-based compensation totaled $109,911 for nine months ended October 31, 2024.
• ·Operating lease right-of-use asset fully impaired to $0 from $89,652.

06-05-2026

Solid Power, Inc. reported total revenue and grant income of $3,073 thousand for Q1 2026, down 49% YoY from $6,016 thousand due to a 59% drop in revenue to $2,105 thousand despite a slight increase in grant income; operating loss widened to $26,346 thousand from $24,029 thousand YoY. However, net loss narrowed to $13,028 thousand ($0.06 per share) from $15,151 thousand ($0.08 per share) YoY, aided by higher nonoperating income, while the balance sheet strengthened with total assets rising 22% QoQ to $554,728 thousand, cash up 46% to $31,509 thousand, and stockholders' equity up 26% to $525,056 thousand, primarily from $121,336 thousand net proceeds of a registered direct offering. Operating cash use improved to $18,753 thousand from $26,291 thousand YoY, though investing activities used $92,288 thousand net mainly from security purchases.

• ·Investments increased to $181,000 thousand as of March 31, 2026 from $86,997 thousand as of Dec 31, 2025 (up 108% QoQ).
• ·Warrant liabilities decreased to $4,240 thousand from $13,881 thousand QoQ.
• ·Shares issued in registered direct offering: 22,807,018 shares.

06-05-2026

Standex International Corp reported robust Q3 FY2026 results with net sales increasing 8% YoY to $224,595 thousand, gross profit up 12% to $91,932 thousand, and net income attributable to common stockholders surging to $66,978 thousand from $21,880 thousand, driven by a $56,837 thousand gain on sale of business; nine-month sales rose 17% YoY to $663,346 thousand with net income to $84,155 thousand. However, total assets declined 3% to $1,526,777 thousand from $1,566,880 thousand at June 30, 2025, goodwill fell 4% to $585,503 thousand, inventories remained flat at $129,563 thousand, and other comprehensive loss included $39,427 thousand in foreign currency translation losses for the nine months.

• ·Diluted EPS total for three months ended March 31, 2026: $5.55 (up from $1.81 YoY)
• ·Diluted EPS total for nine months ended March 31, 2026: $6.98 (up from $3.41 YoY)
• ·Restructuring costs three months: $2,989 thousand (up from $1,976 thousand YoY)
• ·Weighted average diluted shares three months March 31, 2026: 12,062 thousand
• ·Dividends declared nine months: $1.00 per share ($12,030 thousand total)

06-05-2026

Cricut, Inc. reported Q1 2026 total revenue of $159,471 thousand, down 1.8% YoY to $162,634 thousand, with Platform revenue up 6.0% to $84,768 thousand but Products revenue declining 9.6% to $74,703 thousand. Net income decreased 15.0% to $20,318 thousand from $23,914 thousand, reflecting a 22.0% drop in operating income to $22,886 thousand despite relatively flat operating expenses. Stockholders' equity rose 4.1% quarter-over-quarter to $357,491 thousand, bolstered by net income, though cash and equivalents fell 7.7% to $236,499 thousand.

• ·Operating cash flow declined sharply 56.1% YoY to $26,853 thousand from $61,166 thousand.
• ·Deferred revenue ended Q1 2026 at $57,442 thousand, up from $53,281 thousand at start of period.
• ·Common stock repurchases totaled $12,261 thousand in Q1 2026.
• ·Cash dividends paid $21,157 thousand in Q1 2026.

06-05-2026

Clear Channel Outdoor Holdings, Inc. reported Q1 2026 revenue of $373.9M, up 11.9% YoY from $334.2M, driven by growth in continuing operations. However, operating income declined 12.2% YoY to $39.5M from $45.0M due to higher corporate expenses (up 55.8%) and other operating expenses, resulting in a net loss attributable to the Company of $48.6M versus a $62.5M profit in Q1 2025, largely from sharply lower discontinued operations income. Cash and cash equivalents decreased to $182.4M from $190.0M at year-end, with operating cash flow dropping 78.4% YoY to $3.2M.

• ·Direct operating expenses increased 6.9% YoY to $180.1M.
• ·Selling, general and administrative expenses rose 4.6% YoY to $66.6M.
• ·Interest expense, net improved slightly to $98.5M from $99.4M YoY.
• ·Capital expenditures were $16.0M in Q1 2026, down from $25.5M YoY.
• ·Stockholders’ deficit widened to $(3,438.3M) from $(3,394.4M) at year-end.

06-05-2026

Talos Energy Inc. reported Q1 2026 revenues of $472,310, down 8% YoY from $513,059, primarily due to lower oil (-7%) and NGL (-42%) sales while natural gas remained flat; a $145,018 impairment charge drove a net loss of $256,004 versus $9,868 in Q1 2025. Operating cash flow declined 35% to $174,001 but stayed positive, and total assets decreased to $5,272,720 from $5,552,057 at year-end 2025 amid higher depletion. The company repurchased $38,203 in treasury stock, contributing to reduced stockholders' equity.

• ·DD&A expense decreased 18% YoY to $230,384.
• ·Equity method investment income of $6,670 in Q1 2026 vs expense prior year.
• ·Capital expenditures $152,422 in Q1 2026, up 18% YoY.
• ·Proceeds from sale of equity method investment $49,665.
• ·Interest paid $57,741, slightly down YoY.

06-05-2026

Bristow Group Inc. reported Q1 2026 total revenues of $388.7M, up 10.9% YoY from $350.5M, driven by strong 25.4% growth in Government Services to $107.9M and 6.1% in Offshore Energy Services to $254.3M. However, net income attributable to Bristow fell 52.1% YoY to $13.1M from $27.4M, due to a $2.8M loss on debt extinguishment, higher net interest expense of $13.8M, and unfavorable other net expense of $5.4M, despite a modest 3.4% rise in operating income to $34.7M. Cash from operations was negative $8.3M, worse than negative $0.6M prior year, though cash and equivalents rose to $342.1M at quarter-end.

• ·Long-term debt increased to $727.4M at Mar 31 2026 from $643.5M at Dec 31 2025 amid $500M borrowings and $404M repayments.
• ·Net cash used in operating activities $8.3M in Q1 2026 vs $0.6M in Q1 2025.
• ·Treasury stock purchases $11.0M in Q1 2026; dividends declared $3.8M ($0.125/share).
• ·Total assets $2.41B at Mar 31 2026, up from $2.31B at Dec 31 2025.

06-05-2026

YUM Brands reported strong Q1 2026 results with total revenues up 15% YoY to $2,059 million, driven by 29% growth in company sales to $785 million and 9% in franchise and property revenues to $856 million. Operating profit rose 17% to $644 million and net income surged 71% to $432 million, with diluted EPS at $1.55, though company restaurant expenses increased 30% to $677 million. Operating cash flow edged up 3% to $416 million, while share repurchases continued at $185 million.

• ·Short-term borrowings increased significantly to $1,741 million from $38 million at year-end 2025.
• ·Long-term debt decreased to $10,213 million from $11,872 million at year-end 2025.
• ·Dividends declared per common share $0.75 vs $0.71 YoY.
• ·Share repurchases $185 million in Q1 2026 vs $229 million in Q1 2025.
• ·Income tax provision $84 million vs $176 million YoY.

06-05-2026

Match Group reported Q1 2026 revenue of $863.9M, up 4% YoY from $831.2M, driven by strong Hinge growth of 28% to $194.5M, while Tinder grew modestly 2% to $454.7M; however, Evergreen & Emerging declined 7% to $139.1M, Match Group Asia fell 6% to $59.5M, and Indirect revenue dropped 14% to $16.1M. Operating income rose 37% YoY to $236.4M with cost reductions, leading to net income of $166.8M (up 42% YoY), though total assets decreased slightly to $4.4B and shareholders' equity remained negative at -$218M.

• ·Diluted EPS $0.68 in Q1 2026 vs $0.44 in Q1 2025.
• ·Long-term debt, net $3,550M as of March 31, 2026, stable QoQ.
• ·Operating cash flow flat at ~$194M YoY.
• ·Dividend declared $0.20 per share in Q1 2026 (vs $0.19 in Q1 2025).
• ·Treasury stock purchases $60.1M in Q1 2026 (down from $195.6M in Q1 2025).

06-05-2026

Ultragenyx reported Q1 2026 total revenues of $136M, slightly down 2% YoY from $139M, with product sales at $89M (-2% YoY) and royalty revenue at $47M (-2% YoY). Operating expenses rose 8% YoY to $305M, driven by a 13% increase in R&D to $187M, resulting in a widened net loss of $185M (-23% YoY worse than $151M) and EPS of ($1.84). Cash and equivalents dropped sharply to $175M as of March 31, 2026 from $421M at year-end 2025, with net cash used in operations increasing to $197M from $166M YoY.

• ·Stockholders’ equity deficit worsened to ($236M) at Mar 31 2026 from ($80M) at Dec 31 2025.
• ·Total liabilities decreased slightly to $1,525M from $1,605M QoQ.
• ·Stock-based compensation expense was $30M in Q1 2026 vs $40M in Q1 2025.

06-05-2026

AMD reported strong Q1 FY2026 results with net revenue surging 38% YoY to $10,253 million from $7,438 million, gross profit up 45% to $5,416 million, operating income up 83% to $1,476 million, and net income nearly doubling 95% to $1,383 million. Diluted EPS rose to $0.84 from $0.44. However, operating expenses increased 34% YoY to $3,940 million driven by higher R&D (up 39%) and inventories grew 2% QoQ to $8,045 million.

• ·Cash flows from operating activities surged 215% YoY to $2,955 million.
• ·Total current assets increased to $28,628 million from $26,947 million QoQ.
• ·Long-term debt stable at $2,350 million.
• ·Stock repurchases totaled $221 million in Q1 FY2026.

06-05-2026

Lumentum Holdings Inc. reported strong Q3 FY2026 results with net revenue of $808.4 million, up 90% YoY from $425.2 million, and net income of $144.2 million versus a $44.1 million loss prior year; nine-month revenue reached $2,007.7 million (+73% YoY from $1,164.3 million) with net income of $226.6 million reversing a $187.4 million loss. Gross profit surged 191% YoY to $357.0 million in Q3, while operating income turned positive at $174.5 million from a $37.7 million loss. However, cost of sales rose 52% YoY to $432.1 million in Q3, R&D expenses increased 19% to $90.6 million, and current portion of long-term debt ballooned to $3,238.6 million from $10.6 million.

• ·Cash provided by operating activities for nine months FY2026: $388.4 million (up from $62.3 million YoY).
• ·Payments for acquisition of property, plant and equipment: $284.5 million for nine months FY2026.
• ·Payment for acquisition of business: $38.0 million.
• ·Total assets as of March 28, 2026: $7,027.9 million (up from $4,218.7 million as of June 28, 2025).
• ·Stockholders’ equity as of March 28, 2026: $2,973.4 million (up from $1,134.7 million as of June 28, 2025).

06-05-2026

Revenues for BJ's Restaurants Inc increased 2.9% YoY to $358,118 thousand in the thirteen weeks ended March 31, 2026, driven by modest growth in sales. However, income from operations declined 29.0% to $10,623 thousand due to higher restaurant operating costs, depreciation and amortization (up 25% to $22,812 thousand), and loss on disposal and impairment of assets (up significantly to $1,746 thousand), resulting in net income of $9,034 thousand, down 33.1% YoY. Total assets decreased to $999,067 thousand from $1,015,455 thousand at year-end 2025, while long-term debt was reduced to $62,000 thousand from $85,000 thousand.

• ·Diluted EPS declined to $0.41 from $0.58 YoY.
• ·Cash and cash equivalents decreased slightly to $22,671 thousand from $23,781 thousand QoQ.
• ·Weighted average diluted shares outstanding decreased to 21,892 from 23,284 YoY due to repurchases.
• ·Net cash used in investing activities was $15,744 thousand, similar to $16,647 thousand prior year.
• ·Common stock repurchases totaled $5,302 thousand in the current period.

06-05-2026

Arista Networks reported robust Q1 2026 results with total revenue of $2,709.0 million, up 35.1% YoY from $2,004.8 million, led by 36.6% growth in product revenue to $2,311.3 million and 27.3% in services to $397.7 million. Net income rose 25.7% to $1,022.9 million, operating income increased 34.8% to $1,157.8 million, and net cash from operations surged 164% to $1,693.5 million. However, other comprehensive loss of $31.3 million led to comprehensive income of $991.6 million (up 20.2% YoY), and the company paused common stock repurchases this quarter after $787.1 million in Q1 2025.

• ·Deferred revenue increased to $4,909.5 million current as of March 31, 2026 from $4,002.6 million at year-end 2025.
• ·Stock-based compensation expense was $120.9 million in Q1 2026, up from $93.0 million in Q1 2025.
• ·No common stock repurchases in Q1 2026 compared to $787.1 million in Q1 2025.

06-05-2026

Atkore Inc. reported net sales growth of 4% YoY to $731M for the three months ended March 27, 2026, and 2% YoY to $1.39B for the six months, but gross profit declined sharply 27% YoY to $136M in the quarter due to higher cost of sales. Operating income improved to $10M from a $52M loss YoY, however a $137M litigation settlement and $26M other expenses drove a wider net loss of $124M in the quarter (vs $50M loss prior) and $109M for six months (vs $4M loss). Cash from operations swung to a $27M use from $161M provided in the prior six-month period.

• ·Total assets stable at $2.85B as of March 27, 2026 vs September 30, 2025.
• ·Inventories decreased to $401M from $485M year-to-date.
• ·Accounts receivable increased to $558M from $447M year-to-date.
• ·Net cash used in operating activities $27M for six months vs provided $161M prior year.
• ·Capital expenditures $26M for six months vs $64M prior year.

06-05-2026

QuidelOrtho Corp reported total revenues of $619.8M for Q1 FY2026, down 10.5% YoY from $692.8M, driven by sharp declines in Point of Care (-34.0% to $112.8M) and Donor Screening (-39.1% to $7.8M), while Immunohematology grew 7.6% to $138.3M and Labs dipped 5.3% to $353.1M. Net loss widened to $91.8M from $12.7M YoY, with operating loss of $31.8M versus $32.6M income, and higher interest expense of $51.1M. Cash and equivalents fell to $140.4M from $169.8M QoQ amid $33.0M operating cash use versus $65.6M provided YoY.

• ·Inventories increased $33.9M QoQ to $611.5M.
• ·Accounts receivable decreased $57.1M QoQ to $359.9M.
• ·Restructuring charges fell to $4.4M from $16.1M YoY.
• ·Capital expenditures $34.0M in Q1 FY2026 versus $56.2M YoY.
• ·Basic loss per share $(1.35) versus $(0.19) YoY.

06-05-2026

Pinnacle Financial Partners reported Q1 2026 net income of $150M, up 7% YoY from $140M, driven by net interest income growth of 156% to $933M and non-interest revenue up 193% to $284M, largely from the Synovus acquisition which doubled total assets to $122,766M and loans to $84,255M net. However, non-interest expenses surged 246% to $952M due to $275M merger costs and higher salaries, provision for credit losses rose 347% to $76M, EPS diluted to $0.89 from $1.78, and comprehensive income fell to $48M from $142M amid OCI losses.

• ·Merger-related expense of $275M in Q1 2026.
• ·Allowance for loan losses increased to $942M from $442M QoQ.
• ·Acquisition net cash impact: $2,537M.
• ·Cash dividends on common stock: $0.50 per share ($75M total) in Q1 2026 vs $0.24 ($19M) in Q1 2025.

06-05-2026

Astera Labs reported strong Q1 2026 results with revenue surging 93% YoY to $308,361 thousand from $159,442 thousand, gross profit rising 97% to $235,141 thousand, operating income increasing 448% to $61,833 thousand, and net income up 152% to $80,310 thousand. However, cash and equivalents declined 12% QoQ to $148,285 thousand from $167,611 thousand amid $94,007 thousand net cash used in investing activities, including $65,049 thousand for business combinations. Total assets grew 8% QoQ to $1,659,215 thousand, driven by higher goodwill to $87,725 thousand.

• ·Stock-based compensation expense of $52,883 thousand recognized in Q1 2026, up from $42,446 thousand in Q1 2025.
• ·Goodwill increased to $87,725 thousand as of March 31, 2026 from $19,015 thousand as of December 31, 2025.
• ·Accounts receivable, net, rose 62% QoQ to $134,797 thousand from $83,202 thousand.
• ·Unrealized loss on marketable securities of $5,090 thousand in Q1 2026, compared to gain of $1,602 thousand in Q1 2025.

06-05-2026

Primoris Services Corp reported Q1 2026 revenue of $1,559.9M, down 5.4% YoY from $1,648.1M, with gross profit declining 21.1% to $134.7M amid higher cost of revenue. Operating income fell sharply 65.3% to $24.4M due to elevated SG&A expenses ($105.8M, up 6.3%) and transaction costs ($4.5M), resulting in net income of $17.4M versus $44.2M YoY. Cash used in operations was $122.6M, compared to $66.2M provided last year, with cash and equivalents dropping to $361.5M from $535.5M QoQ.

• ·Net cash used in operating activities: $122.6M in Q1 2026 vs $66.2M provided in Q1 2025.
• ·Purchase of property and equipment: $27.8M in Q1 2026 vs $40.6M in Q1 2025.
• ·Dividends declared: $0.08 per common share, $4.3M payable.
• ·Basic EPS: $0.32 in Q1 2026 vs $0.82 in Q1 2025.
• ·Total stockholders’ equity increased slightly to $1,684.0M from $1,681.0M QoQ.

06-05-2026

For the quarter ended March 27, 2026, Fresh Del Monte Produce Inc reported net sales of $1,044.1 million, down 5% YoY from $1,098.4 million, with gross profit declining 3% to $89.0 million and operating income dropping 55% to $20.1 million primarily due to $20.0 million in asset impairments and higher SG&A expenses. Net income fell to $10.7 million from $31.9 million YoY. However, the company completed the acquisition of select assets from Del Monte Foods for $307.7 million net of cash acquired, contributing to total assets rising 11% QoQ to $3,402.4 million and cash increasing to $66.3 million from $35.7 million QoQ.

• ·Dividends declared per ordinary share remained flat at $0.30 for Q1 2026.
• ·Asset impairments of $16.1 million in cash flow adjustments for Q1 2026.
• ·Proceeds from debt of $266.9 million in financing activities, likely related to the acquisition.
• ·Net assets acquired from Del Monte Foods totaled $341.9 million.

06-05-2026

Flywire Corp reported Q1 2026 revenue of $188,112 thousand, up 40.9% YoY from $133,452 thousand, driven by 48% growth in Americas to $93,913 thousand, 35% in EMEA to $64,243 thousand, and 33% in APAC to $29,956 thousand, achieving operating income of $10,782 thousand and net income of $12,518 thousand versus a $10,988 thousand operating loss and $4,160 thousand net loss in Q1 2025. Transactions revenue rose 43% to $155,205 thousand while platform revenues grew 32% to $32,907 thousand. However, cash and equivalents declined 5.7% QoQ to $311,893 thousand from $330,303 thousand, total assets fell 7.2% to $1,162,379 thousand, and operating cash flow used $15,848 thousand, though improved from $80,794 thousand used YoY.

• ·Stock-based compensation expense of $18,034 thousand in Q1 2026, up slightly from prior periods.
• ·Common stock repurchases of $10,031 thousand in Q1 2026.
• ·Funds payable to clients decreased $109,420 thousand QoQ to $201,379 thousand.

06-05-2026

JBT Marel Corp reported net income of $45 million for Q1 2026, a significant turnaround from a $173 million net loss in Q1 2025, driven by operational improvements and absence of prior-year acquisition costs. Cash provided by operating activities rose sharply to $119 million from $34 million YoY, boosting cash and equivalents to $211 million (up QoQ from $168 million). However, comprehensive income declined to $26 million from $73 million YoY due to $19 million other comprehensive loss from foreign currency translation and derivatives, while total assets dipped slightly to $8,163 million QoQ from $8,191 million.

• ·Depreciation and amortization increased to $68M in Q1 2026 from $61M YoY.
• ·Capital expenditures were $26M in Q1 2026 vs $20M YoY.
• ·Final Marel goodwill in purchase allocation: $2,322M after $340M measurement period adjustment.
• ·Customer relationships in Marel PPA reduced to $1,160M after $410M adjustment.
• ·Common stock cash dividends: $0.10 per share, totaling $5M in Q1 2026.

06-05-2026

Taboola.com Ltd. reported Q1 2026 revenues of $466,395 thousand, up 9.1% YoY from $427,493 thousand, with gross profit increasing 8.6% to $129,577 thousand. The company achieved a net income of $59,066 thousand, swinging from a $8,750 thousand loss in Q1 2025, bolstered by $77,000 thousand in other income, leading to operating income of $69,384 thousand versus a $6,262 thousand loss. However, cost of revenues rose 9.3% to $336,818 thousand, operating expenses excluding other income increased across R&D (+10.1%), sales & marketing (+10.1%), and G&A (+5.6%), and shareholders' equity declined to $955,330 thousand from $1,008,209 thousand year-over-year.

• ·Net cash used in financing activities: $(60,662) thousand Q1 2026 vs $(51,248) thousand Q1 2025.
• ·Repurchase of Ordinary shares: 6,885,750 shares for $(23,633) thousand in Q1 2026.
• ·Cash and cash equivalents increased $29,410 thousand quarter-over-quarter to $150,275 thousand.

06-05-2026

ITC Holdings Corp. reported Q1 2026 net income of $137M, up 7.9% YoY from $127M, with total operating revenues rising 7.5% to $473M driven by a 9.1% increase in transmission and other services to $433M. However, operating expenses increased 10.1% to $218M and formula rate true-up revenues declined 7.0% to $40M from $43M. Total assets grew 2.5% QoQ to $15,205M as of March 31, 2026 from $14,834M at December 31, 2025, supported by higher property, plant and equipment.

• ·Net cash used in investing activities increased to $400M in Q1 2026 from $349M in Q1 2025 due to higher capex.
• ·Cash and cash equivalents decreased to $3M as of March 31, 2026 from $13M at December 31, 2025.
• ·Commercial paper program size $400M with $381M issued and outstanding at weighted average interest rate of 4.07%.
• ·Dividends to ITC Investment Holdings remained flat at $73M YoY.

06-05-2026

06-05-2026

For the three months ended March 31, 2026, CVS Health reported total revenues of $100,426 million, up 6.2% YoY from $94,588 million, with strong growth in products (+7.8% to $62,226 million) and services (+7.1% to $3,835 million), while premiums grew modestly +3.0% to $33,791 million. Net income attributable to CVS Health surged 65.4% YoY to $2,943 million, with diluted EPS rising to $2.30 from $1.41. However, net cash provided by operating activities declined 6.7% to $4,249 million from $4,556 million, operating expenses dipped slightly -0.7% but total operating costs rose 5.0%, and total assets decreased marginally to $252,974 million from $253,538 million at December 31, 2025.

• ·Cash and cash equivalents increased QoQ to $9,542 million from $8,453 million.
• ·Inventories decreased QoQ to $17,770 million from $19,246 million.
• ·Current liabilities declined QoQ to $86,406 million from $88,692 million.
• ·Shareholders' equity attributable to CVS Health rose to $77,456 million from $75,214 million at year-end.

06-05-2026

For Q1 2026 ended March 31, total revenue declined 56% YoY to $6,472 thousand amid sharp drop in operating revenue to $6,301 thousand from $14,818 thousand, while grant revenue improved to $171 thousand from ($73) thousand. Operating expenses fell 35% YoY to $134,977 thousand, leading to a narrower net loss of $117,504 thousand versus $202,487 thousand prior year and reduced operating cash use to $81,101 thousand from $131,957 thousand. Stockholders' equity stood at $1,024,769 thousand at quarter-end, down from $1,130,865 thousand at December 31, 2025.

• ·Operating revenue declined 57% YoY to $6,301 thousand.
• ·Research and development expenses decreased to $87,896 thousand from $129,634 thousand.
• ·Cash, cash equivalents and restricted cash decreased $88,741 thousand during the quarter to $665,180 thousand.
• ·Accrued expenses and other liabilities fell to $54,205 thousand from $70,230 thousand at December 31, 2025.

06-05-2026

United Therapeutics reported total revenues of $781.5 million for Q1 2026, down 1.6% YoY from $794.4 million, while operating expenses increased 10.7% to $455.7 million, resulting in operating income of $325.8 million (-14.9% YoY) and net income of $274.9 million (-14.7% YoY). Diluted EPS fell to $5.82 from $6.63. However, net cash from operating activities remained robust at $463.3 million (flat +0.5% YoY), supported by a significant $1,500.0 million share repurchase.

• ·Total assets decreased to $6,714.2 million as of March 31, 2026 from $7,880.0 million as of December 31, 2025.
• ·Treasury stock increased to $(5,441.6) million as of March 31, 2026 from $(4,260.4) million as of December 31, 2025 due to repurchases.
• ·Net cash used in financing activities was $1,484.4 million in Q1 2026, primarily from $1,500.0 million share repurchases.

06-05-2026

For Q1 2026, LeMaitre Vascular Inc reported net sales of $66,551 thousand, up 11.2% YoY from $59,871 thousand, with gross profit rising 16.9% to $48,396 thousand and net income increasing 42.4% to $15,679 thousand. However, total operating expenses grew 6.4% to $30,621 thousand, driven by a 14.9% rise in general and administrative expenses to $12,046 thousand, while R&D expenses remained flat and cash equivalents declined QoQ to $26,851 thousand from $28,244 thousand.

• ·Diluted EPS increased to $0.68 from $0.48 YoY.
• ·Cash dividends declared per common share rose to $0.25 from $0.20.
• ·Net cash provided by operating activities up 67.0% YoY to $15,093 thousand.
• ·Short-term marketable securities increased QoQ to $340,382 thousand from $330,876 thousand.
• ·Stockholders’ equity grew QoQ to $406,622 thousand from $393,516 thousand.

06-05-2026

06-05-2026

Utz Brands reported Q1 2026 net sales of $361.3M, up 2.6% YoY from $352.1M, with gross profit rising 11.5% to $91.9M and operating income increasing 36.8% to $7.8M driven by higher sales and a gain on asset sales. However, selling expenses surged 23.1% to $51.1M, leading to a net loss of $2.4M versus $5.7M profit YoY, and cash and equivalents declined 38.8% QoQ to $73.7M amid operating cash use of $12.2M. Total assets dipped slightly to $2,786.1M, with equity decreasing to $1,337.4M.

• ·Inventories increased to $122.5M from $119.3M QoQ.
• ·Property, plant and equipment net remained flat at $379.9M QoQ.
• ·Total liabilities stable at $1,448.7M YoY.
• ·Share-based compensation expense $3.9M in Q1 2026.

06-05-2026

TIC Solutions, Inc. reported Q1 2026 revenue of $488,029, a 108% YoY increase from $234,215, with gross profit surging 269% to $161,301. However, selling, general and administrative expenses rose sharply to $150,328 from $39,872, interest expense increased to $29,021 from $16,007, leading to a wider net loss of $41,549 versus $25,793 YoY and loss per share of $0.19 versus $0.21. Cash and equivalents declined to $426,564 from $439,536 QoQ, with operating cash flow dropping 70% to $9,925 from $32,792 YoY.

• ·Business acquisitions used $3,884 net cash in Q1 2026.
• ·Depreciation and amortization $40,036 in Q1 2026 vs $13,237 YoY.
• ·Weighted-average common shares basic: 217,251,178 in Q1 2026 vs 121,476,215 YoY.
• ·Supplemental interest paid $26,673 in Q1 2026.

06-05-2026

Hut 8 Corp. reported Q1 2026 revenue of $71,017, a 226% YoY increase driven by Compute segment growth to $65,974 from $16,118, while Power revenue declined to $3,740 from $4,380 and Digital Infrastructure remained nearly flat at $1,303 versus $1,317. However, massive losses on digital assets of $295,657 (up from $112,394) and higher G&A expenses of $81,740 contributed to an operating loss of $(370,370) and net loss attributable to Hut 8 of $(219,849), worsening from $(133,889) YoY. Cash position strengthened to $160,016 from $44,914 QoQ, supported by $190,997 in financing inflows mainly from stock issuances.

• ·Sale of Far North JV generated net proceeds of $63,601 in investing activities.
• ·Non-controlling interests increased to $310,337 from $267,545 QoQ.
• ·Property and equipment, net rose to $812,373 from $643,244 QoQ.
• ·Digital assets held in custody declined to $435,720 from $661,979 QoQ.

06-05-2026

NiSource Inc. reported Q1 2026 total operating revenues of $2,363.1 million, up 8.3% YoY from $2,183.2 million, with customer revenues rising 8.1% to $2,322.3 million. Operating income increased 7.9% to $819.2 million and net income attributable to NiSource grew 6.8% to $507.1 million ($1.06 diluted EPS, up from $1.00); however, operation and maintenance expenses surged 14.4% to $489.2 million, depreciation rose 11.5% to $288.3 million, and interest expense jumped 44.3% to $191.6 million. Total assets expanded to $36,601.0 million as of March 31, 2026, from $35,858.7 million at year-end 2025.

• ·Net income attributable to noncontrolling interests decreased to $49.1 million in Q1 2026 from $51.9 million in Q1 2025.
• ·Short-term borrowings increased to $1,291.0 million as of March 31, 2026, from $736.0 million at December 31, 2025.
• ·Net Property, Plant and Equipment rose to $29,427.4 million as of March 31, 2026, from $28,688.2 million at December 31, 2025.

06-05-2026

For the quarter ended March 28, 2026, Disney's total segment revenues rose 6.5% YoY to $25,168 million from $23,621 million, with Entertainment up 9.7% to $11,715 million and Experiences up 6.7% to $9,487 million, while Sports grew modestly 1.6% to $4,609 million. Segment operating income increased 3.7% YoY to $4,603 million; however, net income declined 27.5% to $2,465 million from $3,401 million. Over the six months ended March 28, 2026, revenues grew 5.9% to $51,149 million, but segment operating income fell 3.0% to $9,203 million from $9,496 million and net income dropped 18.1% to $4,949 million from $6,045 million.

• ·Cash provided by operations six months: $7,649 million vs $9,958 million prior year (-23.1%).
• ·Investments in parks, resorts and other property six months: $4,986 million.
• ·Total current liabilities: $36,223 million as of March 28, 2026 vs $34,162 million prior quarter.
• ·Borrowings: $38,471 million long-term + $8,887 million current as of March 28, 2026.

06-05-2026

For Q1 2026, Brink’s revenues grew 10.3% YoY to $1,375.1M, with strong contributions from all regions including Europe (+14.8% to $365.9M) and Latin America (+11.9% to $343.8M). However, operating profit declined 7.5% to $110.2M amid higher cost of revenues (+8.5% to $1,019.4M) and a sharp 34.6% rise in SG&A expenses to $250.8M, resulting in net income attributable to Brink’s dropping 37.8% to $32.1M and diluted EPS of $0.77 (down from $1.18). Cash flow from operations improved significantly to $28.7M from a $60.2M outflow in Q1 2025.

• ·Share repurchases in Q1 2026: 0.2 million shares for $28.6M.
• ·Cash dividends paid per common share: $0.2550 (up from $0.2425 YoY).
• ·Capital expenditures: $40.1M in Q1 2026 (down from $58.9M YoY).
• ·Net cash used in investing activities: $36.2M in Q1 2026.
• ·Net cash used in financing activities: $151.8M in Q1 2026.
• ·Segment operating profit Q1 2026: North America $60.9M, Latin America $57.4M, Europe $39.9M, Rest of World $55.0M (total $213.2M).

06-05-2026

For Q1 2026, Centrus Energy reported total revenue of $76.7M, up 5% YoY from $73.1M, driven by strong growth in Technical Solutions (+47% to $32.1M) and new Uranium sales ($3.0M), though Separative Work Units revenue declined 19% to $41.6M. Gross profit dipped 4% to $31.5M amid higher costs, leading to operating income falling sharply to $0.8M from $20.5M primarily due to elevated advanced technology costs of $18.9M, while net income decreased 63% to $10.0M. Operating cash flow swung to a use of $35.1M from generation of $36.5M YoY, with cash and equivalents down QoQ to $1,868.2M.

• ·Advanced technology costs increased to $18.9M from $3.0M YoY.
• ·Capital expenditures were $23.2M in Q1 2026 vs $2.1M prior year.
• ·Long-term debt steady at approximately $1,176.1M.
• ·Russian Federal Decree No. 1516 extends export restrictions through December 31, 2027.

06-05-2026

For the three months ended March 31, 2026, X4 Pharmaceuticals reported total revenue of $2,708 thousand, a 91% YoY decline from $28,807 thousand primarily due to lower license revenue ($239 thousand vs. $27,865 thousand), though product revenue grew 162% YoY to $2,469 thousand. Operating expenses decreased 40% YoY to $23,014 thousand, driven by reductions in R&D (down 17%) and G&A (down 54%), but the company swung to a net loss of $20,241 thousand from a $282 thousand profit in Q1 2025. Cash and equivalents remained nearly flat QoQ at $216,908 thousand as of March 31, 2026 (down <1% from $217,049 thousand at Dec 31, 2025), with total assets down 7% to $270,281 thousand and stockholders' equity down 10% to $168,450 thousand.

• ·Net cash used in operating activities increased 59% YoY to $19,599 thousand in Q1 2026 from $12,368 thousand.
• ·Weighted average basic shares outstanding: 126,288,723 in Q1 2026 vs. 6,840,035 in Q1 2025.
• ·Restricted cash: $579 thousand as of Mar 31, 2026 (down from $803 thousand at Dec 31, 2025).

06-05-2026

Immunocore Holdings plc reported Q1 2026 total revenue of $106,677, up 13.6% YoY from $93,881, with U.S. revenue growing 19.1% to $67,438, Europe up 4.9% to $34,413, and International up 8.0% to $4,826. Net income increased sharply to $12,971 from $5,023, and operating income swung to a profit of $7,280 from a loss of $3,616. However, cash and cash equivalents decreased QoQ to $452,675 from $467,709, with net cash used in operating activities at $13,775 versus provided $435 YoY, and total comprehensive income was nearly flat at $5,682 versus $5,696.

• ·Total current assets increased QoQ to $1,003,807 from $996,742.
• ·Selling, general and administrative expense decreased YoY to $37,850 from $40,198.
• ·Provisions for rebates, chargebacks, and returns totaled $144,524 as of March 31, 2026.
• ·Cash paid for interest was $5,031 in both Q1 2026 and Q1 2025.

06-05-2026

Palmer Square Capital BDC Inc. (PSBD) reported a net decrease in net assets resulting from operations of $37,236,966 for the three months ended March 31, 2026, worsening from $8,389,211 in the prior year period, primarily due to unrealized losses of $37,599,190 and realized losses of $10,674,426. Total investment income declined 16% YoY to $26,216,714 while net investment income fell 15% to $11,036,650; however, total expenses decreased 17% to $15,180,064. Net assets dropped 11% QoQ to $413,782,758 with NAV per share declining to $13.30 from $14.85.

• ·Cash and cash equivalents decreased to $1,489,202 as of March 31, 2026 from $3,217,449 at December 31, 2025.
• ·Credit facilities (net) reduced to $400,443,711 from $414,438,758 QoQ.
• ·Common shares repurchased for $1,588,747 in Q1 2026.
• ·Net cash provided by operating activities was $29,052,714 in Q1 2026, down from $46,413,351 in Q1 2025.

06-05-2026

Tucson Electric Power Co's operating revenues for the three months ended March 31, 2026 declined 7.5% YoY to $338,267 thousand from $365,736 thousand, driven by lower sales volumes. Net income fell sharply 39.5% YoY to $26,897 thousand from $44,431 thousand, due to higher operations and maintenance expenses (+12.3% YoY) despite lower fuel and purchased power costs (-17.2% YoY). Operating cash flows saw a modest 1.9% YoY increase to $130,828 thousand, while capital expenditures decreased 9.7% YoY to $156,156 thousand.

• ·Total Utility Plant, Net increased to $7,168,257 thousand as of March 31, 2026 from $7,053,145 thousand as of December 31, 2025.
• ·Plant in Service grew to $9,079,327 thousand as of March 31, 2026 from $9,000,669 thousand as of December 31, 2025.
• ·Dividends paid to parent: $150,000 thousand in Q1 2026.
• ·Contributions from parent: $95,000 thousand in Q1 2026.